Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 167 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Etanercept Clear all
Not listed Phase 4 Interventional

Etanercept Therapy for Nails Psoriasis Monitoring With Noninvasive Imaging

NCT05135312
View directory record Official record
Conditions
Psoriasis, Psoriatic Arthritis, Psoriatic Nail
Interventions
Etanercept, OCT
Drug · Device
Lead sponsor
OptiSkin Medical
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 17, 2026, 1:33 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol

NCT00679042
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islets of Langerhans transplantation
Biological
Lead sponsor
CellTrans Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 17, 2026, 1:33 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Efficacy and Mechanisms of an Antiinflammatory Intervention for Chemotherapy Related Mucosal Injury

NCT00031551
View directory record Official record
Conditions
Stomatitis
Interventions
Etanercept, Placebo
Drug
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
16 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Phase 1 Interventional

TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset

NCT04254627
View directory record Official record
Conditions
Gulf War Illness
Interventions
Etanercept, Mifepristone
Drug
Lead sponsor
Nova Southeastern University
Other
Eligibility
45 Years to 70 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Davie, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Phase 1Phase 2 Interventional

Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes

NCT00093366
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
etanercept, arsenic trioxide
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 30, 2011 · Synced Oct 17, 2026, 1:33 AM EDT
Withdrawn Phase 4 Interventional

Human Tumor Necrosis Factor Alpha (TNFa)-Induced Pre-B Cell Bone Marrow Emigrants

NCT01009879
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression

NCT00566813
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Islet Cell Transplant, Islet Cell Transplant plus
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

RHYTHM (Formerly Escape II Myocardium)

NCT01548768
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
TNF inhibitors, DMARDs
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Phase 4 Interventional Results available

IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

NCT02451748
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Lab Work, Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg), Certolizumab pegol (CDP870, tradename Cimzia), Hydroxychloroquine, Sulfasalazine, Medrol, Prednisone, Triamcinolone, Naproxen, Leflunomide, Methotrexate, humira
Other · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Phase 4 Interventional Results available

A Study of Baricitinib in Participants With Rheumatoid Arthritis

NCT04086745
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Baricitinib, TNF Inhibitor
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
119
States / cities
Chandler, Arizona • Mesa, Arizona • Paradise Valley, Arizona + 104 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 17, 2026, 1:33 AM EDT
Terminated Phase 4 Interventional Results available

Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)

NCT00796705
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab, Adalimumab placebo, Etanercept
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
16
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Immunological Basis for Treatment Resistance to Anti-TNF Treatments

NCT01971346
View directory record Official record
Conditions
Psoriasis
Interventions
etanercept
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Phase 2Phase 3 Interventional

Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome

NCT00111956
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
Etanercept, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Phase 2 Interventional

Etanercept to Treat Wegener's Granulomatosis

NCT00001901
View directory record Official record
Conditions
Vasculitis, Wegener's Granulomatosis
Interventions
Etanercept
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma

NCT00201838
View directory record Official record
Conditions
Pancreatic Neoplasms, Adenocarcinoma
Interventions
Gemcitabine, Etanercept
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 30, 2017 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Not applicable Interventional

Study of TNF-Antagonism in Metabolic Syndrome

NCT00409318
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Etanercept, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2008 · Synced Oct 17, 2026, 1:33 AM EDT
Completed No phase listed Observational

Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation

NCT02330380
View directory record Official record
Conditions
Psoriasis, Inflammation
Interventions
Methotrexate, Ustekinumab, Etanercept, Adalimumab, Acitretin, UVB Excimer Laser, Narrowband UVB
Drug · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 17, 2026, 1:33 AM EDT
Not listed Phase 4 Interventional

An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use

NCT01132235
View directory record Official record
Conditions
Psoriasis
Interventions
etanercept
Biological
Lead sponsor
Florida Academic Dermatology Centers
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 28, 2010 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Phase 4 Interventional Results available

Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial

NCT01400516
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Teriparatide, calcium citrate, Vitamin D, TNF antagonist
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients

NCT00888628
View directory record Official record
Conditions
Diabetes Mellitus, Type I
Interventions
Purified Pancreatic Islets, Etanercept
Biological · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Phase 2 Interventional

Etanercept With Tacrolimus for Psoriasis

NCT00134394
View directory record Official record
Conditions
Psoriasis
Interventions
Etanercept plus tacrolimus
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 7, 2008 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Phase 4 Interventional Results available

Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept

NCT01875991
View directory record Official record
Conditions
Rheumatoid Arthritis, Plaque Psoriasis
Interventions
Etanercept via Autoinjector A, Etanercept via Autoinjector B
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
28
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Glendale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Oct 17, 2026, 1:33 AM EDT
Terminated Phase 1 Interventional Results available

Effects of Denosumab on the Pharmacokinetics of Etanercept

NCT01294397
View directory record Official record
Conditions
Postmenopausal, Osteopenia, Rheumatoid Arthritis, Osteoporosis
Interventions
Etanercept, Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Duncansville, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Can We Miss Pigmented Lesions in Psoriasis Patients?

NCT01053819
View directory record Official record
Conditions
Psoriasis, Melanoma, Non-melanoma Skin Cancer
Interventions
etanercept
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 17, 2026, 1:33 AM EDT